Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Brigatinib in Japanese Patients With ALK-Positive NSCLC
jRCT2080223767Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in ALK-positive non-small cell lung cancer, sponsored by Takeda. Started Jan 2018; status: completed.
02
Drugs
brigatinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080223767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223767.